Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6

Gayathri Nagaraj, Yousef Zarbalian, Karin Flora, Benjamin R. Tan

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Small bowel adenocarcinoma is an uncommon gastrointestinal malignancy with limited data on effective chemotherapy in the adjuvant setting, as well as for advanced disease. We present a case report of a patient with recurrent duodenal adenocarcinoma after resection and adjuvant chemotherapy who experienced a complete response to bevacizumab with oxaliplatin and 5FU (FOLFOX) followed by bevacizumab/capecitabine maintenance therapy for 2 years. The patient continues to be disease-free 8 years after his recurrence. This case highlights the potential of vascular endothelial growth factor (VEGF) inhibitors to enhance chemotherapeutic regimens for advanced small bowel adenocarcinoma.

Original languageEnglish
Pages (from-to)E1-E6
JournalJournal of Gastrointestinal Oncology
Volume5
Issue number1
DOIs
StatePublished - Feb 2014

Keywords

  • Bevacizumab
  • Capecitabine
  • Oxaliplatin
  • Small bowel adenocarcinoma

Fingerprint

Dive into the research topics of 'Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6'. Together they form a unique fingerprint.

Cite this